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1 |  INTRODUCTION
For a number of species in which the cardiac ventricular ac-
tion potential (AP) exhibits a high plateau phase (including 
guinea-pig, rabbit, dog and—importantly—human), the 
rapid delayed rectifier K+ current (IKr) contributes signifi-
cantly to ventricular AP repolarization and to setting the 
duration of the QT interval of the ECG (Gima & Rudy, 
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Abstract
The macrolide antibiotic erythromycin has been associated with QT interval pro-
longation and inhibition of the hERG-encoded channels responsible for the rapid 
delayed rectifier K+ current I(Kr). It has been suggested that low concentrations of 
erythromycin may have a protective effect against hERG block and associated drug-
induced arrhythmia by reducing the affinity of the pore-binding site for high po-
tency hERG inhibitors. This study aimed to explore further the notion of a potentially 
protective effect of erythromycin. Whole-cell patch-clamp experiments were per-
formed in which hERG-expressing mammalian (Human Embryonic Kidney; HEK) 
cells were preincubated with low to moderate concentrations of erythromycin (3 or 
30 µM) prior to whole-cell patch clamp recordings of hERG current (IhERG) at 37°C. 
In contrast to a previous report, exposure to low concentrations of erythromycin did 
not reduce pharmacological sensitivity of hERG to the antipsychotic thioridazine 
and antihistamine terfenadine. The IC50 value for IhERG tail inhibition by terfenadine 
was decreased by ~32-fold in the presence of 3 µM erythromycin (p <  .05 vs. no 
preincubation). Sensitivity to thioridazine remained unchanged (p > .05 vs. no prein-
cubation). The effects of low concentrations of erythromycin were investigated for a 
series of pore blocking drugs, and the results obtained were consistent with additive 
and/or synergistic effects. Experiments with the externally acting blocker BeKm-1 
on WT hERG and a pore mutant (F656V) were used to explore the location of the 
binding site for erythromycin. Our data are inconsistent with the use of erythromycin 
for the management of drug-induced QT prolongation.
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2002; Sanguinetti & Jurkiewicz, 1991; Tamargo, Caballero, 
Gomez, Valenzuela, & Delpon, 2004; Virag et al., 2001). 
The pore-forming (α) subunit of IKr is encoded by hERG 
(human Ether-à-go-go Related Gene; alternative nomen-
clature KCNH2) and functional channels are comprised 
of hERG subunit tetramers (Sanguinetti, Jiang, Curran, & 
Keating, 1995). Unique structural features, including the 
presence of specific aromatic amino acid residues (tyro-
sine at 652 & phenylalanine at 656; Y652 and F656) in 
the S6 helices of the channel, are believed to contribute to 
hERG’s sensitivity to pharmacological blockade (Hancox, 
McPate, El Harchi, & Zhang, 2008; Sanguinetti & Tristani-
Firouzi, 2006; Vandenberg, Walker, & Campbell, 2001). 
Structurally diverse drugs in clinical use produce hERG 
blockade as an unwanted side effect. This carries a risk of 
prolongation of the QT interval of the electrocardiogram 
which, in turn, is associated with a risk of the potentially 
fatal arrhythmia Torsade de Pointes (TdP) (Hancox et al., 
2008; Vandenberg et al., 2001). The treatment of drug-in-
duced long QT syndrome (diLQTS) and TdP is largely sup-
portive until levels of the drug in question have fallen along 
with the QT interval (Yap & Camm, 2003). A drug that 
could selectively reverse hERG channel blockade would 
therefore be an attractive adjunct or replacement treatment 
as well as being able to provide novel insight into how 
hERG blockade might be avoided in drug development. In 
recent years a number of hERG channel agonists (activa-
tors) have been identified. In principle, such drugs could 
produce “functional” antagonism of hERG blocking drugs 
(Meng, Shi, Li, Du, & Xu, 2013), not necessarily through 
impairing drug-binding per se, but by increasing current 
through unblocked channels.
It has been suggested that erythromycin, a macrolide 
antibiotic drug, which in high concentrations can cause 
QT interval prolongation (Crumb, 2014), may at low con-
centrations have a protective effect against hERG block by 
reducing the affinity of the pore-binding site for high po-
tency hERG inhibitors with no apparent change to hERG 
kinetics (Crumb, 2014). The effects of two potent hERG 
inhibitors (the antipsychotic thioridazine and the with-
drawn antihistamine terfenadine) on IhERG were found to 
be attenuated by pretreatment of a hERG-expressing mam-
malian cell line with erythromycin (at erythromycin con-
centrations producing 10% or less block of IhERG) (Crumb, 
2014). The results of that study were interpreted to raise 
the possibility of antagonistic allosteric interactions be-
tween drug-binding sites on the external and internal face 
of the hERG channel (Crumb, 2014) and it is possible 
for hERG-blocking compounds to have relatively weak 
interactions with residues of the canonical drug-binding 
site (Duncan et al., 2006; Mitcheson, 2003). However, 
at present there is only limited evidence for the putative 
protective effect of erythromycin and its associated site 
of action. To inform conceptual development of treatment 
approaches to diLQTS, we aimed in this study to: (a) char-
acterize erythromycin's potential interactions with a selec-
tion of pore and nonpore hERG inhibitors and (b) provide 
further information as to where on the channel erythromy-
cin potentially interacts to modulate hERG pore blocker 
action.
2 |  MATERIAL AND METHODS
2.1 | Mutagenesis
The F656V hERG mutation (Lees-Miller, Duan, Teng, & Duff, 
2000) was generated using the QuickChange® site-directed mu-
tagenesis kit (Stratagene). In brief, a pair of complementary ol-
igonucleotide primers containing the mutation (forward primer 
sequence 5′GTATGCTAGCATCGTCGGCAACGTGTCG3′ 
and reverse primer sequence 5′ CGACACGTTGCCGACG 
ATGCTAGCATAC3′, synthesized by Sigma-Genosys) was 
used in a PCR reaction (95°C for 1 min, 60°C for 1 min, 68°C 
for 16 min for 18 cycles) with hERG in a modified pcDNA3.0 
vector as a DNA template. A DpnI digest of the PCR mix was 
then performed for 1 hr at 37°C. Competent DH5α Escherichia 
coli (Invitrogen) were transformed using standard procedures. 
The mutation was confirmed by sequencing of the entire open 
reading frame (Eurofins MWG Operon).
2.2 | Maintenance of HEK cells and cell 
transfection
Human Embryonic Kidney (HEK-293) cells stably express-
ing WT hERG were kindly donated by Prof Craig January. 
HEK 293 cells used for transient transfection were obtained 
from ECACC (catalog number 85120602). Cells were pas-
saged using a nonenzymatic agent (Enzyme Free, Chemicon 
International®) and maintained as previously described 
(McPate, Duncan, Milnes, Witchel, & Hancox, 2005; Milnes, 
Crociani, Arcangeli, Hancox, & Witchel, 2003; Ridley, 
Dooley, Milnes, Witchel, & Hancox, 2004). For transient 
transfection experiments, 24 hr after plating cells out, cells 
were transiently transfected with 0.5 µg of the F656V hERG 
construct using LipofectamineTM LTX (Invitrogen) accord-
ing to the manufacturer's instructions. Expression plasmid 
encoding CD8 was also added as a transfection marker (El 
Harchi, Zhang, Hussein, Dempsey, & Hancox, 2012). Cells 
were plated onto small sterilized glass coverslips 6 hr after 
transfection and recordings were made after at least 24 hr 
incubation at 37°C. Successfully transfected cells were 
identified using Dynabeads® (Invitrogen). All experimental 
data for the F656V hERG mutant channel were obtained 
from cells from a minimum of two transfections.
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2.3 | Electrophysiological recordings
For whole-cell patch-clamp recording cells were continu-
ously superfused at physiological temperature (37°C) with 
an external solution containing (in mM): 140 NaCl, 4 KCl, 
2.5 CaCl2, 1 MgCl2, 10 Glucose and 5 HEPES (titrated to pH 
7.45 with NaOH). Patch-pipettes (Corning 7052 glass, AM 
Systems) were pulled and heat-polished (Narishige MF83) 
to 2.5–4 MΩ; pipette dialysate contained (in mM): 130 KCl, 
1 MgCl2, 5 EGTA, 5 MgATP, 10 HEPES (titrated to pH 7.2 
using KOH). Recordings of hERG current (IhERG) and were 
made using an Axopatch 200 amplifier (Axon Instruments) 
and a CV201 head-stage. Between 70%–80% of pipette series 
resistance was compensated. Voltage-clamp commands were 
generated using “WinWCP” (John Dempster, Strathclyde 
University).
2.4 | Drug selection and preparation
Erythromcyin's actions were investigated for a range of 
drugs selected on the basis of their known arrythmogenic 
potential, potency of block, interaction site within the pore 
of the hERG channel and/or state-dependent kinetics of 
block. The withdrawn antihistamine terfenadine and an-
tipsychotic thioridazine (nM IC50) (Crumb, 2000; Milnes, 
Witchel, Leaney, Leishman, & Hancox, 2006) were se-
lected to test the reported effect of low concentrations of 
erythromycin on IhERG block by these drugs under our con-
ditions (Crumb, 2014). Dofetilide (high affinity [nM IC50]) 
(Milnes, Witchel, Leaney, Leishman, & Hancox, 2010) is 
an archetypal selective (“methanesulfonanilide”) hERG 
blocker, with some risk of TdP (Hancox et al., 2008; Yap 
& Camm, 2003). Chloroquine (low μM IC50) is an antima-
larial agent that exhibits a fast-open block for the hERG 
channel (Sánchez-Chapula, Navarro-Polanco, Culberson, 
Chen, & Sanguinetti, 2002) and can prolong the QT in-
terval (Bustos, Gay, Diquet, Thomare, & Warot, 1994; 
Khobragade et al., 2013). The antifungal ketoconazole 
(low μM IC50) is an imidazole relative of clotrimazole (pre-
viously reported to produce additive or slightly synergistic 
block of IhERG in combination with erythromycin (Crumb, 
2014), but unlike clotrimazole is known to bind within the 
pore (Ridley et al., 2006). Disopyramide (low μM IC50) is 
a class Ia antiarrythmic agent inhibitor that binds low in the 
hERG channel's inner cavity, which renders the inhibitory 
effects of disopyramide poorly dependent on inactivation 
(El Harchi et al., 2012; McPate et al., 2005). The peptide 
toxin BeKm-1 exhibits preferential closed channel block 
(Milnes, Dempsey, et al., 2003). This toxin was selected 
because it interacts with the S5-pore linker/outer vesti-
bule of the channel from the external surface (Tseng et al., 
2007).
Erythromycin was dissolved in ethanol (Sigma) to produce 
a stock solution of 50 mM. Chloroquine and disopyramide-di-
phosphate (Sigma-Aldrich) were dissolved in deionized water 
(Milli-Q, Millipore) at a stock concentration of 50  mM. 
Terfenadine, ketoconazole and thioridazine (Sigma-Aldrich) 
were dissolved in methanol to produce stock solutions of 
10  mM. All stock solutions were diluted to produce stock 
solutions ranging down to 1  mM with at least 1:1000-fold 
final dilution with Tyrode's solution to achieve concentrations 
stated in the Results. At such dilutions, the stock solution ve-
hicles used have been shown not to significantly affect IhERG 
amplitude (Himmel, 2007; Tie et al., 2000). In house Fmoc-
synthesized BeKm-1 (Milnes, Dempsey, et al., 2003) was dis-
solved in sterile 10 mM Tris–HCl, 1 mM EDTA, pH 7.6 to 
produce stock solutions of 25 μM. Stock solutions were ali-
quoted into glass vials and stored at −20°C before use (Milnes, 
Dempsey, et al., 2003). External solutions were applied using 
a home-built, warmed, and rapid solution exchange device 
(Levi, Hancox, Howarth, Croker, & Vinnicombe, 1996).
2.5 | Electrophysiology data analysis
Concentration–response relations were fitted with a standard 
Hill equation to obtain half-maximal inhibitory concentration 
(IC50) and Hill-coefficient (nH) values (GraphPad Prism v.7) 
of the form:
Drug combination index (DCI) values were calculated to 
measure and quantify the effects on IhERG produced by drug 
combination, using the following equation (Chou, 2006):
where the denominators A(x)1 and B(x)1 stand for the concen-
trations of test substances A and B, with each inhibiting hERG 
peak tail currents by x%, and the numerators are concentrations 
A1 and B1 which, in combination, also inhibit hERG peak tail 
currents by x%. The A(x)1 and B(x)1 values were derived from 
Equation 1. A Combination Index value equal to 1 indicates 
additivity. A value greater or smaller than 1 indicates, respec-
tively, antagonism or synergism (Chou, 2006).
Time courses of IhERG inhibition were fitted using either a 
single (Equation 3) exponential decay fit of the forms:
Mean values in the text are presented either as mean ± SEM 
or (for IC50 and nH values) as mean ± 95% confidence inter-
vals (CI) from n = 4 to 10 cells per experiment. Statistical 
analysis was performed using unpaired t tests or one-way and 
two-way analysis of variance as appropriate (Sigmaplot v13) 
with Bonferroni post hoc test. Tests used are specified in the 
(1)Fractional block=1∕
(
1+
(
IC
50
∕ [DRUG]
)
nH
)
(2)DCI=A1∕A(x)1+B1∕B(x)1
(3)Y=
(
Y0−Plateau
)
∗ exp (−K∗X)+Plateau.
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relevant figure legends. P values of less than 0.05 were taken 
as statistically significant.
3 |  RESULTS
3.1 | hERG sensitivity to erythromycin, 
terfenadine, and thioridazine
Figure 1 shows the concentration dependence of IhERG inhibi-
tion by erythromycin, terfenadine and thioridazine under the 
recording conditions of this study, with representative traces 
of effects of single drug concentrations shown in Figure 1ai–
ci and concentration–response relations shown in Figure 1aii–
cii. IhERG traces were elicited by the voltage protocol shown in 
the lower panels of Figure 1ai–ci (a standard command proto-
col used in previous studies of IhERG pharmacology from our 
laboratory (e.g., El Harchi et al., 2012; Milnes et al., 2010; 
Zhang, Colenso, Sessions, Dempsey, & Hancox, 2011)). 
IhERG “tail” magnitude was measured relative to instantane-
ous current at −40 mV elicited by the brief (50 ms) depo-
larizing step that preceded the voltage command to +20 mV 
in the absence and presence of the drug. Consistent with a 
previous report from our laboratory (Duncan et al., 2006), 
3  µM and 30  µM erythromycin reduced IhERG tail, respec-
tively, by 22.5 ± 3.5% (n = 8 cells) and 42.6 ± 9.3% (n = 6 
cells) within 6-min of drug superfusion. A range of eryth-
romycin concentrations between 0.3 and 600 µM was then 
tested and a concentration response relation constructed. The 
half maximal inhibitory concentration (IC50) derived from a 
standard Hill equation was 94 μM (CI 38.4 μM to 230.1 μM; 
n = 5 to 8 cells per concentration) with a Hill coefficient (nH) 
of 0.40 (CI 0.25–0.54; cf [Stanat, Carlton, Crumb, Agrawal, 
& Clarkson, 2003]). This is in fair agreement with previously 
published IC50 values of 59.3 μM (Duncan et al., 2006) and 
72.2 µM (Volberg, Koci, Su, Lin, & Zhou, 2002). A fit to 
the concentration–response data for inhibition of IhERG tail 
by terfenadine yielded an IC50 value of 128.5 nM (CI 68.0–
243.3 nM; n = 4 to 6 cells per concentration) and an nH of 
0.57 (CI 0.36–0.77 nM). Finally, thioridazine was found to 
inhibit IhERG tails with an IC50 of 62 nM (CI 52.7–73.1 nM; 
n = 5 to 7 cells per concentration) and an nH of 0.55 (CI 0.50–
0.61). We also assessed the effects of drug block on IhERG 
time constants of deactivation. Tail currents on repolarization 
to −40mV were fitted using a biexponential to derive the fast 
τ1 and slow τ2 time constants of deactivation in control and 
after drug application. The estimated fast time constant τ1 and 
slow time constant τ2 were, respectively, 158.0 ± 20.5 ms 
and 1,196.1 ± 103.1 ms in control (n = 6 cells). At 6-min 
of exposure to 30 µM erythromycin, the fast component of 
deactivation was slowed but the slow component remained 
unchanged: τ1 was 232.4  ±  33.6  ms (n  =  6 cells; p  <  .05 
F I G U R E  1  Sensitivity of IhERG to erythromycin (a), terfenadine (b) and thioridazine (c). Top panels show representative traces for IhERG 
recorded at 37ºC before and during exposure to 3 or 30 µM erythromycin (Ery) (ai), 100 nM terfenadine (Terf) (bi) or 100 nM thioridazine (Thior) 
(ci). Currents were elicited using the protocol shown in the lower panels. Bottom panels show the isochronal concentration–response relationships 
obtained for erythromycin (aii) (IC50 94 µM (CI 38.4–230.1 µM); n = 5 to 8 to cells per concentration), terfenadine (bii) (IC50 128.5 nM (CI 
68.0–243.3 nM); n = 4 to 6 to cells per concentration) and thioridazine (cii) (IC50 62 nM (CI 52.7–73.1 nM); n = 5 to 7 cells per concentration). 
Respective nH values yielded from fit were of 0.40 (CI 0.25–0.54), 0.57 (CI 0.36–0.77), 0.55 (CI 0.50–0.61) for erythromycin, for terfenadine and 
for thioridazine
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vs. control) and τ2 was 1,335.1 ± 185.4 ms in erythromycin 
(n = 6; cells p > .05 vs. control). The proportion of deactivat-
ing current fitted by the fast component τ1 was ∼0.6 and ~0.4 
for the slow component τ2. None of these values was signifi-
cantly different between control and following drug applica-
tion (p > .05 vs. in control). No change to the time constants 
of deactivation was observed following exposure to 100 nM 
terfenadine or 100 nM thioridazine (p > .05 and p > .05 vs. 
control; n = 6 and 7 cells, respectively).
3.2 | Sensitivity to terfenadine and  
thioridazine of IhERG recorded from 
erythromycin pretreated cells
Since the substantial inhibitory effect on IhERG at higher con-
centrations (≥30 μM) would preclude the use of such erythro-
mycin concentrations to protect against hERG channel block 
by other drugs, we predominantly focused our investigation 
on the effects of a low concentration of 3 μM erythromycin, 
as reported in (Crumb, 2014). Figure 2 shows the effects of 
a 15-min preincubation with 3 µM erythromycin on the con-
centration dependence of IhERG inhibition by terfenadine and 
thioridazine, with representative traces of effects of single 
drug concentrations shown in Figure 2ai–bi and concentra-
tion–response relations shown in Figure 2aii–bii. 100 nM ter-
fenadine reduced IhERG tail by 66.7 ± 11.1% (n = 5; p > .05 
vs. in the absence of erythromycin). Two other terfenadine 
concentrations were tested in the continuous presence of 
3  µM erythromycin and a concentration–response relation 
was constructed, yielding an IC50 of 4 nM (CI 0.63–25.6 nM; 
n = 5 cells per concentration) with a Hill coefficient (nH) of 
0.3 (CI 0.14–0.47). Superimposition (as dashed line) of the 
concentration–response relation for inhibition of IhERG tail in 
the absence of 3 µM erythromycin was made to allow com-
parison between the two conditions. These data indicate that, 
under the conditions of this study, exposure to a low con-
centration of erythromycin resulted in a ~32-fold increase in 
IhERG sensitivity to terfenadine as shown in Figure 2aii. In 
order to assess further the effects of a pretreatment with 3 µM 
erythromycin on hERG sensitivity to terfenadine, we also 
calculated the drug combination index (DCI); recognized as 
F I G U R E  2  Effect of a pretreatment with 3 µM erythromycin on IhERG block by terfenadine (a) and thioridazine (b). Left panels show 
representative current traces for effects of 100 nM terfenadine (ai) or 100 nM thioridazine (bi) on IhERG after a 15-min preincubation with 
3 µM erythromycin. Currents were elicited using the protocol shown in the lower panels. Right panels show isochronal concentration–response 
relationships for terfenadine inhibition of IhERG (aii) or thioridazine (bii) in the presence of 3 µM erythromycin. Fit to the concentration–response 
curves yielded an IC50 of 4 nM ((CI 0.63–25.6 nM); n = 5 cells per concentration) for terfenadine and 46.4 nM ((CI 36.3–59.3 nM); n = 4 to 6 cells 
per concentration) for thioridazine. Respective nH were of 0.30 (CI 0.14–0.47) for terfenadine and of 0.73 (CI 0.58–0.90) for thioridazine. Asterisks 
in Aii denote statistical significance: ** at p < .01 and *p at < .05 (two-way ANOVA with Bonferroni post hoc test)
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a gold standard measure of drug combination effects (Chou, 
2006): a DCI of 0.06 was obtained which would be indicative 
of strong synergism (Chou, 2006).
In contrast to its effect on terfenadine, 3 µM erythromy-
cin exposure did not affect IhERG block by thioridazine. The 
IC50 for IhERG tail inhibition by thioridazine in the presence of 
erythromycin was 46.4 nM (CI 36.3–59.3 nM; n = 4 to 6 cells 
per concentration; nH = 0.73 [CI 0.58–0.90]) which does not 
differ from the calculated IC50 value for IhERG inhibition in 
the absence of erythromycin as represented by the respective 
overlapping concentration–response curves in Figure 2bii 
(p > .05).
3.3 | Effects of erythromycin on IhERG 
inhibition by different pore blocking inhibitors
The differences in effects of preincubation with 3  µM 
erythromycin on IhERG sensitivity to terfenadine and 
thioridazine suggests that results of erythromycin expo-
sure could vary between different pore-blocking drugs. 
Additional experiments were therefore conducted to as-
sess the effects of low concentrations of erythromycin (i.e., 
≤30 µM) on IhERG tail block by a series of hERG pore in-
hibitors exhibiting varying blocking/interaction properties 
(for selection see also Methods). In addition to terfenadine 
and thioridazine, dofetilide, chloroquine, and ketoconazole 
were tested. Results obtained under conventional voltage 
clamp for all five drugs are summarized in Table 1. Effects 
were studied of preincubation with either 3 µM or 30 µM 
erythromycin on IhERG sensitivity to a concentration close 
to the IC50 value for each of the different blockers selected. 
These experiments showed that increasing erythromycin 
concentration from 3 to 30 µM had limited effect on terfen-
adine and thioridazine block. IhERG block by dofetilide was 
significantly increased in the presence of erythromycin. 
Thus, 10 nM dofetilide reduced IhERG tails by 52.1 ± 3.0% 
(n = 6). In the presence of 3 µM or 30 µM erythromycin, 
IhERG block by dofetilide was significantly increased, re-
spectively, to 66.0 ± 4.8% (n = 5, p < .05 vs. in the absence 
of erythromycin) and 68.9  ±  2.8% (n  =  5 cells, p  <  .01 
vs. in the absence of erythromycin and p > .05 vs. in the 
presence of 3  µM erythromycin). Similarly, exposure to 
3  µM erythromycin or 30  µM erythromycin was associ-
ated with increased hERG block by chloroquine (Table 1). 
Finally, sensitivity to ketoconazole of IhERG tail recorded 
from erythromycin-pretreated cells was similar to that of 
IhERG recorded in the absence of the macrolide (Table 1). 
Given the lack of protective effect of a pretreatment with 
erythromycin, we also checked whether reversing the order 
of application could influence results (data not shown). 
Superfusion of 3 µM erythromycin following steady state 
of hERG block was associated either with additive drug 
effects for some pore inhibitors or no effect for others. 
Erythromycin at a single concentration of 3 µM failed to 
block currents exposed to 100 nM terfenadine or 3 µM ke-
toconazole. In contrast, superfusion of 3 µM erythromycin 
was associated with 43.4 ± 6.1% (n = 5 cells; p < .05 vs. 
in the absence of dofetilide) and 70.0 ± 11.7% (n = 5 cells; 
p < .01 vs. in the absence of thioridazine) of hERG block, 
respectively, in the presence of 10 nM dofetilide or 100 nM 
thioridazine. In the presence of 1 µM chloroquine, the per-
centage of IhERG tail inhibition was 43.7  ±  3.0% (n  =  5; 
p < .01 vs. in the absence of chloroquine). Overall, our data 
suggest that under the conditions of this study low concen-
trations of erythromycin had no protective effect against 
pharmacological blockade of hERG. For some inhibitors 
results were consistent with additive and/or possibly syn-
ergistic interactions that vary with the order of application 
and the nature of the pore inhibitor tested.
[Erythromycin] 0 µM 3 µM 30 µM
Terfenadine 100 nM 45.0 ± 5.2 (n = 6) 66.7 ± 11.8 (n = 5) 71.4 ± 9.7 (n = 5)
Thioridazine 100 nM 54.4 ± 4.6 (n = 6) 63.5 ± 7.3 (n = 6) 63.3 ± 4.3 (n = 5)
Dofetilide 10 nM 52.1 ± 3.0 (n = 6) 66.0 ± 4.8 (n = 5)* 68.9 ± 2.8 (n = 5)**
Chloroquine 1 µM 48.4 ± 3.9 (n = 5) 70.8 ± 5.3 
(n = 5)***
77.8 ± 0.6 
(n = 4)***
Ketoconazole 3 µM 47.5 ± 5.0 (n = 7) 59.5 ± 3.9 (n = 7) 55.5 ± 5.3 (n = 7)
Note:: To enable comparison between the three experimental conditions tested, % of IhERG tail inhibition values 
calculated as the fractional block of outward IhERG tail at −40 mV were time matched. For each drug, IhERG 
tail was measured at steady state of block which occurred within 8–10 min of drug superfusion for dofetilide, 
terfenadine and thioridazine, 6-min for ketoconazole and 3-min for chloroquine. Columns show mean ± SEM 
values. The numbers in parentheses represent the number of cells tested.
*Denotes statistically significant difference from in absence of erythromycin at p < .05. 
**Denotes significance at p < .01. 
***Denotes significance at p < .001 (One Way ANOVA with Bonferroni post-hoc test). 
T A B L E  1  Isochronal percentage of 
hERG block by diverse hERG pore blockers 
in absence or in presence of erythromycin
   | 7 of 14EL HARCHI Et AL.
3.4 | Investigating the molecular basis for 
erythromycin effect on hERG pharmacological 
sensitivity
It has been suggested that erythromycin may bind to an ex-
ternal site that would participate in the pharmacological 
modulation of hERG’s block by pore inhibitors (Crumb, 
2014). In previous work from our laboratory mutation of 
the canonical inhibitor-binding residue F656 to Ala (hERG 
F656A) produced only a modest reduction in erythromycin 
block (Duncan et al., 2006). However, differences between 
F656A and WT hERG channels require inward IhERG meas-
urement in high external [K+] to obtain sufficiently large 
tail currents. In contrast, the valine mutation of F656 (hERG 
F656V) preserves the current profile of WT hERG in normal 
K+ (Lees-Miller et al., 2000). Therefore, we employed the 
F656V mutation to explore the interaction between eryth-
romycin and the internal pore cavity where most hERG 
blocking drugs bind. Figure 3ai and aii, respectively, show 
representative traces for inhibition of WT and F656V IhERG 
by 600  µM erythromycin, with the protocol shown in the 
lower panels. Mean data comparing percentage of IhERG tail 
inhibition by 600 µM erythromycin is shown in Figure 3b. 
At 6 min of drug superfusion, WT and F656V IhERG were re-
duced, respectively, by 67.2 ± 1.9% (n = 5) and 45.4 ± 3.8% 
(n = 5; p <  .001 vs. WT). This modest reduction in chan-
nel sensitivity to erythromycin is in good agreement with 
previously reported data obtained for alanine mutation of 
residue F656 (Duncan et al., 2006). Upon drug superfusion, 
IhERG tail current on repolarization to −40  mV exhibited a 
slowing in the rates of deactivation. Tail currents were fitted 
using a biexponential to derive the fast τ1 and slow τ2 time 
constants of deactivation in control and after 6-min superfu-
sion of 600 µM erythromycin. For WT IhERG tails, the time 
constant τ1 was slowed: τ1 was 133.3 ± 22.4 ms in control 
and 300.9 ± 21.2 ms in erythromycin (n = 5; p < .01 vs. in 
control). No change to the time constant τ2 was observed. In 
contrast, both time constants of deactivation were slowed for 
currents recorded from the mutant channel. The time con-
stant τ1 was 27.9 ± 1.5 ms in control and 64.0 ± 11.9 ms in 
erythromycin (n = 5; p < .05 vs. in control), whereas τ2 was 
286.5 ± 54.2 ms in control and 665.0 ± 81.8 ms in eryth-
romycin (n = 5; p < .05 vs. in control). This change to the 
time constants of deactivation resulted in a crossing-over of 
F656V IhERG currents as displayed in Figure 3aii and was 
observed in all five recordings obtained. Crossing-over of 
tail currents on repolarization is typically associated with a 
“foot in the door” type of blockade (Ducroq, Printemps, & Le 
Grand, 2005; Hreiche, Plante, Drolet, Morissette, & Turgeon, 
2011; Margulis & Sorota, 2008; Sánchez-Chapula et al., 
2002); it indicates that in the case of erythromycin the drug 
may slow closure of the deactivation gate through interaction 
with a noncanonical-binding site.
Without a clear pattern of effects for erythromycin on 
hERG pharmacological sensitivity to its pore inhibitors, 
probing the existence of an external-binding site by way of 
mutagenesis was challenging. To attempt to address this issue 
we used the externally acting blocker BeKm-1, which has a 
known external-binding site (Milnes, Dempsey, et al., 2003; 
Tseng et al., 2007), to investigate whether erythromycin 
F I G U R E  3  Effect of mutation at 
F656 on IhERG block by erythromycin (a) 
Representative traces for WT IhERG (ai) and 
F656V IhERG (aii) before (control) and after 
exposure to 600 µM erythromycin (Ery) 
at 37ºC, using the voltage protocols in the 
panels below. (b) Bar charts comparing 
the level of block produced by 600 µM 
erythromycin of WT (white bar; n = 5) 
and F656V (gray bar; n = 5) IhERG tail on 
repolarization to −40 mV following a 2 s 
depolarization from −80 mV to +20 mV. 
Asterisks in B denote statistical significance: 
** p < .01 (unpaired t test)
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interacts with, or can influence binding to, the S5-pore linker 
region of the hERG channel. BeKm-1 potency against IhERG 
tail was assessed in the absence and in the presence of 3 µM 
erythromycin. Figure 4 shows the effects of 30 nM BeKm-1 
on IhERG tail in the absence and following superfusion of 
3 µM erythromycin; representative traces of effects of 30 nM 
BeKm-1 are shown in Figure 4ai,aii with mean fractional per-
centages of block and values for the time to half inhibition 
(thalf) of IhERG, respectively, shown as bar graphs in Figure 
4b and 4c. Consistent with a previous study from our labo-
ratory (Milnes, Dempsey, et al., 2003), BeKm-1 blockade of 
IhERG exhibited inverse dependence on duration of depolar-
ization (data not shown). Consequently, to ensure adequate 
levels of IhERG block, drug effects for all experiments uti-
lizing BeKm-1 were assessed against IhERG tail elicited by 
a short (400  ms) depolarizing step protocol (shown in the 
lower panel of Figure 4ai,aii). 30 nM BeKm-1 reduced IhERG 
tail by 52.2  ±  3.4% (n  =  10) (Figure 4b). In the presence 
of 3 µM erythromycin, IhERG tail block by 30 nM BeKm-1 
was 46.8 ± 5.0% (n = 6; p > .05 vs. in the absence of 3µM 
erythromycin) (Figure 4b). While the effect of BeKm-1 at 
steady state remained statistically unchanged, the time course 
of IhERG tail inhibition was slowed. Figure 4c shows bar 
graphs for the time to half inhibition (thalf) of IhERG tail by 
30 nM BeKm-1 in the absence and in the presence of 3 µM 
erythromycin. In the absence of 3 µM erythromycin, evalua-
tion of the averaged time course of IhERG inhibition obtained 
for 10 cells yielded a thalf of 15.1 ± 2.1 s. In the presence of 
3 µM erythromycin, thalf was 69.6 ± 20.4 s (n = 6; p < .01 vs. 
in the absence of erythromycin). These experiments showed 
that erythromycin was able to interfere with BeKm-1 block 
of IhERG, suggesting that erythromycin may have an exter-
nal-binding site. However, when we tested sensitivity of 
F656V IhERG tail to 30 nM BeKm-1 in the absence and pres-
ence of 3 µM erythromycin, we found that erythromycin had 
no effect on F656V hERG block by BeKm-1.
Figure 5 shows bar charts for mean fractional percentages 
of F656V IhERG block by 30  nM BeKm-1 (Figure 5a) and 
corresponding mean values for thalf of inhibition (Figure 5b) 
obtained in the absence and presence of 3 µM erythromycin. 
30 nM BeKm-1 reduced F656V IhERG by 74.5 ± 1.6% (n = 5; 
p < .001 vs. WT) with a thalf of IhERG inhibition of 14.2 ± 3.3 s 
(n = 5; p > .05 vs. WT); that is, the F656V mutation enhanced 
BeKm-1 block of hERG. Preapplication of 3 µM erythromy-
cin had no effect on F656V IhERG block by 30 nM BeKm-1. 
In the maintained presence of 3 µM erythromycin, BeKm-1 
block of F656V IhERG at steady state was 69.4 ± 5.1% (n = 5; 
p > .05 vs. in the absence of erythromycin) and a thalf of IhERG 
inhibition of 20.7 ± 4.6 s (n = 5; p > .05 vs. in the absence 
of erythromycin). The enhanced sensitivity of the F656V 
F I G U R E  4  Effects of 3 µM erythromycin on IhERG tail sensitivity to 30nM BeKm-1. (a) Representative current traces for effects of 30 nM 
BeKm-1 on IhERG in the absence (ai) or after superfusion of 3 µM erythromycin (aii). Currents were elicited using the protocol shown in the lower 
panels. (b) Bar charts showing the level of block by 30 nM BeKm-1 of WT IhERG tail in the absence (white bar; n = 10) and presence of 3 µM 
erythromycin (gray bar; n = 6). (c) Bar charts comparing thalfvalues of inhibition of WT IhERG tail in the absence (white bar; n = 10) and presence of 
3µM erythromycin (gray bar; n = 6). BeKm-1 effect on IhERG tail recorded on repolarization to −40mV was calculated as the mean fractional block 
and plotted against time to derive the value for time to half inhibition (thalf) of IhERG tail. ** denotes statistically significant difference from WT at 
p < .01 (unpaired t-test)
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mutant channel to 30  nM BeKm-1 (WT and F656V IhERG 
block by 30 nM BeKm-1 were, respectively, of 52.2 ± 3.4% 
and 74.5  ±  1.6% (p  <  .001 vs. WT)) suggests an effect of 
the pore mutation on binding of BeKm-1 to the external tur-
ret. Each of these observations may be encompassed within 
a model where the effect of the F656V mutation on the con-
formational properties of the external turret results in an im-
pairment of erythromycin binding to its putative external site 
and an enhancement of BeKm-1 binding to its external site. 
External binding of erythromycin affects (slows) the binding 
of BeKm-1 and this effect is attenuated by the disruption of 
erythromycin binding resulting from the F656V mutation. 
However, an allosteric modulation by erythromycin of hERG 
sensitivity to BeKm-1 through an internal-binding site involv-
ing residue F656, cannot be ruled out.
To address this issue, we performed additional experi-
ments with the Class Ia antiarrhythmic agent disopyramide 
(IC50 = 7–10 µM; [El Harchi et al., 2012]), which is known 
to access the open channel and bind within the open pore 
cavity at a site involving residue F656 ([El Harchi et al., 
2012]; see also Methods, Drug Selection and Preparation). 
Figure 6 shows the effects on IhERG of 30 nM BeKm-1 in the 
continuous presence of 3 µM disopyramide, with represen-
tative traces of effects shown in Figure 6a and correspond-
ing mean values for thalf of inhibition obtained in the absence 
and presence of 3 µM erythromycin shown in Figure 6b. As 
shown in Figure 6b, preapplication of 3 µM disopyramide de-
layed the time course of WT hERG block by 30 nM BeKm-1 
(n = 7; p <  .01 vs. in the absence of 3 µM disopyramide). 
However, there was no significant effect of disopyramide on 
BeKm-1 potency at steady-state block (% of IhERG block was 
51.4 ± 4.6% at 6 min of drug superfusion; n = 7; p > .05 vs. in 
the absence of 3 µM disopyramide). These data showed that 
preapplication of 3 µM disopyramide delayed the time course 
of WT hERG inhibition by 30 nM BeKm-1 to a similar extent 
to that of 3 µM erythromycin, which: (a) demonstrates com-
munication between the distinct disopyramide (internal) and 
BeKm-1 (external) binding sites; (b) by analogy, indicates 
that erythromycin could affect the time-course of BeKm-1 
block without necessarily competing for a single-binding site.
F I G U R E  5  Effects of mutation F656V on erythromycin modulation of IhERG sensitivity to 30 nM BeKm-1. (a) Bar charts showing the level 
of block by 30 nM BeKm-1 of F656V IhERG tail in the absence (white bar; n = 5) and presence of 3 µM erythromycin (gray bar; n = 5; p > .05 vs. 
in the absence of erythromycin 3 µM [unpaired t test]). (b) Bar charts comparing thalf values of inhibition of F656V IhERG tails in the absence (white 
bar; n = 5) and presence of 3 µM erythromycin (gray bar; n = 5; p > .05 vs. in the absence of erythromycin 3 µM [unpaired t test]). BeKm-1 effect 
on IhERG tail recorded on repolarization to −40mV was calculated as the mean fractional block and plotted against time to derive the value for time 
to half inhibition thalf of IhERG tail. The F656V mutation increased hERG sensitivity to BeKm-1 in the two experimental conditions tested but did 
not affect the rate of block (cf. Figure 4b and 4c)
F I G U R E  6  Sensitivity of IhERG tail to 30 nM BeKm-1 in the presence of 3 µM disopyramide. (a) Representative traces for IhERG before and 
during exposure to 30 nM BeKm-1 in the continuous presence of 3 µM disopyramide. Currents were elicited using the protocol shown in the lower 
panel. (b) Bar charts comparing thalf values of inhibition by 30 nM BeKm-1 of WT IhERG tail in the absence (white bar; n = 10) and presence of 
3 µM disopyramide (gray bar; n = 7). Asterisks in B denote statistical significance: **p < .01 (unpaired t test)
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4 |  DISCUSSION
In clear contrast to an earlier study reporting a protective 
effect of macrolides against block of hERG overexpressed 
in HEK cells (Crumb, 2014), the results of this study show 
that pretreatment with low concentrations of erythromycin 
does not antagonize the inhibitory effects of normally po-
tent hERG blocking drugs in an equivalent overexpression 
system. Exposure to low concentrations of erythromycin did 
not reduce hERG pharmacological sensitivity to the antipsy-
chotic thioridazine and the antihistamine terfenadine. In fact, 
under the conditions of our study, the IC50 value for IhERG 
tail inhibition by terfenadine was decreased by ~32-fold in 
the presence of 3  µM erythromycin (p  <  .05 vs. no prein-
cubation). This significant shift in sensitivity was associated 
with a DCI calculated value of 0.06 which indicates strong 
synergism (Chou, 2006). The synergetic effect was observed 
for the lowest concentrations of terfenadine, whereas for 
the highest concentrations used the effect was sub-additive. 
Sensitivity to thioridazine in the presence of 3 µM erythro-
mycin remained unchanged (p >  .05 vs. no preincubation). 
Increasing the erythromycin concentration to 30 µM did not 
produce any further effect on either terfenadine or thiori-
dazine potencies. Overall, the results from our investiga-
tion of the effects of low concentrations of erythromycin on 
recombinant channels were consistent with additive and/or 
synergistic effects that vary with the order of application, the 
concentration and nature of the pore inhibitors tested.
4.1 | Effects of combining multiple hERG 
blockers: Our findings in context
Despite the fact that drug-induced QT interval prolongation 
often occurs clinically with coadministration of >1 QT in-
terval prolonging drug (Hancox et al., 2008; Yap & Camm, 
2003), there are only a few in vitro studies examining the 
effects of the combined administration of multiple hERG 
blockers on the hERG channel (e.g., Crumb, 2014; Ducroq 
et al., 2005; Friemel & Zunkle, 2010; Hreiche et al., 2011; 
Kornick et al., 2003; Margulis & Sorota, 2008; Wiśniowska, 
Lisowski, Kulig, & Polak, 2018), and reports on the phar-
macological antagonism of hERG block are scarce (Crumb, 
2014; Hreiche et al., 2011). Prior to the report of a protec-
tive effect of macrolides (Crumb, 2014), one study showed 
that MAPD90- prolongation mediated through IKr block by 
the concomitant application of single concentrations of 
erythromycin or ketoconazole with dofetilide was less than 
the addition of the effects of each drug alone (Hreiche et al., 
2011). This would suggest that the combination of two IKr 
blockers could lead to pharmacological antagonism. We 
did not observe any pharmacological antagonism or rever-
sal of IhERG block associated with the administration of low 
concentrations of erythromycin (≤30 µM) with diverse pore 
and nonpore hERG blockers. However, we did find, con-
sistent with previous reports (Ducroq et al., 2005; Friemel 
& Zunkle, 2010; Hreiche et al., 2011; Kornick et al., 2003; 
Margulis & Sorota, 2008; Wiśniowska et al., 2018), that the 
paired combination of two hERG inhibitors is associated ei-
ther with independent or additive/synergistic effects. In our 
hands, pretreatment with erythromycin was associated with 
either strong synergism (terfenadine, chloroquine), slightly 
less than additive effects (dofetilide and thioridazine) or lim-
ited effects (ketoconazole and BeKm-1). When erythromycin 
was applied after steady-state hERG channel block by thiori-
dazine, dofetilide or chloroquine, erythromycin superfusion 
was associated with a potentiation of hERG block suggest-
ing independent actions. In contrast, currents preinhibited by 
terfenadine or ketoconazole were insensitive to erythromy-
cin. The variability in the nature and degree of the allosteric 
interactions seen in our paired combination studies suggests 
that whether drugs had similar- or dissimilar-binding sites 
within the channel's pore cavity does not greatly influence 
the outcome of combining blockers. However, most stud-
ies examining the effects of combining two hERG inhibi-
tors reported that drugs binding within the pore cavity of 
the hERG channel are most likely to interact with drugs that 
do not (e.g., Ducroq et al., 2005; Friemel & Zunkle, 2010; 
Hreiche et al., 2011; Kornick et al., 2003; Margulis & Sorota, 
2008; Wiśniowska et al., 2018). As an example, Friemel and 
Zunckler's study characterized the potential interactions be-
tween a drug inhibitor binding within the pore cavity with 
drugs binding elsewhere on the hERG channel (Friemel & 
Zunkle, 2010); drugs were selected on the basis of their spe-
cific interaction with the hERG channel. They showed that 
compounds with overlapping-binding sites within the pore 
cavity do not interact and their pairwise combination was as-
sociated with additive inhibitory effects (terfenadine in com-
bination with dofetilide). In contrast, the externally acting 
hERG inhibitor CnErg1 slightly antagonized the inhibitory 
effects of terfenadine, whereas chlorobutanol, a drug thought 
to bind to an unidentified site outside the pore cavity, was 
found in combination with terfenadine to inhibit IhERG syn-
ergistically. Surprisingly, fluvoxamine, which like erythro-
mycin was shown to have limited interaction with residue 
F656 and has been suggested to bind at the outer mouth of 
the pore (Milnes, Crociani, et al., 2003; Mitcheson, 2003), 
did not influence IhERG block by terfenadine. A subsequent 
modeling study, however, showed that although fluvoxam-
ine has weak interactions with residue F656, its trifluoro-
methyl group could interact with the nonaromatic residues 
T623 and S624 (Stansfeld et al., 2007). This suggests that 
terfenadine and fluvoxamine may have overlapping-binding 
sites and thus explain the lack of interactions when the two 
drugs are simultaneously applied (Friemel & Zunkle, 2010). 
These findings highlight the complexity of the interactions 
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of drug compounds with their respective binding sites and 
underpin the need for a comprehensive approach combining 
both functional studies with evidence for the location of bind-
ing sites. The data presented in this report are consistent with 
an external site for erythromycin, but we cannot, however, 
rule out some contribution from erythromycin binding to an 
intracellular domain of hERG. Erythromycin may therefore 
act through two different binding sites, one intracellular site 
involving residue F656 likely to be involved in low affinity 
block of the channel (Duncan et al., 2006), and another site 
located on the extracellular side of the channel that may par-
ticipate in the modulation of hERG pharmacological block 
by pore inhibitors. Our data also revealed possible allosteric 
interactions between binding sites on the external and inter-
nal face of the channel, which mirrors previous evidence for 
communication between the extracellular turret of hERG and 
the drug-binding site below the selectivity filter, especially in 
relation to inactivation gating (Ju et al., 2009; Perrin, Kuchel, 
Campbell, & Vandenberg, 2008). The evidence for internal 
and external sites for erythromycin makes it challenging, 
however, to identify a clear pattern of effects for the con-
comitant application of erythromycin with multiple hERG 
blockers.
4.2 | Implications and limitations
The present work and the previous study by Crumb (Crumb, 
2014) each highlight the potential for distinct drug-binding 
sites on hERG that may interact allosterically. However, de-
spite broadly similar experimental conditions, including the 
use of a similar  heterologous expression system for stable 
expression of WT hERG, similar recording solutions near 
physiological temperatures and equivalent incubation times 
with low concentrations of erythromycin; they differ mark-
edly in respect of the presence/absence of a protective ef-
fect of erythromycin on IhERG inhibition by other drugs. 
Experimental details regarding how pretreatment with a low 
erythromycin concentration was performed in (Crumb, 2014) 
are sparse and this precludes detailed comparison of the two 
investigations in this regard. The basic voltage protocol used 
to elicit IhERG in the two studies has some differences and 
it is conceivable that these might have contributed to the 
differences in results of the two studies. However, the dif-
ferences in holding potential of −75 mV in (Crumb, 2014) 
versus −80 mV here and test voltage (+10 mV in (Crumb, 
2014) and +20 mV here) are small and not anticipated to af-
fect fundamentally the results obtained. A depolarizing test 
pulse duration of 2 s was used here versus 500 ms in the ear-
lier study (Crumb, 2014). At near physiological temperatures 
hERG should be substantially activated at the test potentials 
used within 500 ms (Zhou et al., 1998). The longer pulse du-
ration used here might allow longer for drugs to bind to gated 
channels during membrane depolarization. However, steady-
state block for high-affinity drugs that become trapped in 
the hERG channel (such as terfenadine: Stork et al., 2007) 
may not be much impacted by this difference. Indeed, we 
performed some additional experiments with thioridazine to 
compare effects of 500 ms depolarizing steps to +20mV and 
2s depolarizing steps on drug effects on IhERG tails at −40mV. 
We found 3 µM erythromycin alone to inhibit IhERG tail by 
24.8 ± 3.9% with a 500 ms test pulse (n = 6; p > .05 vs. a 2s 
depolarizing step). 100  nM thioridazine reduced WT IhERG 
tail by 52.0 ± 4.4% with a 500 ms test pulse (n = 5; p > .05 
vs. a 2s depolarizing step) and 65.1 ± 4.1% (n = 5; p > .05 
vs. in the absence of 3 µM erythromycin and p > .05 vs. a 2s 
depolarizing step), respectively, in the absence and presence 
of 3 µM erythromycin. These results argue against a major 
role for voltage protocol in underlying the different findings 
of the two studies. The basis for the differences in findings 
of the two studies is therefore not clear at the present time.
The ultimate aim of a comprehensive understanding of 
IKr/hERG pharmacology in relation to diLQTS is enhanced 
safety of drug use in patients and in drug development 
(Hancox et al., 2008; Sanguinetti & Tristani-Firouzi, 2006). 
Among the known risk factors increasing the susceptibil-
ity of individuals to diLQTS, the coadministration of more 
than one hERG-blocking drug (Hancox et al., 2008; Yap & 
Camm, 2003) is a common practice in a clinical setting and 
an issue that physicians have to take into account when copre-
scribing drugs. Drug induced QT prolongation resulting from 
the combination of two or more inhibitors that share meta-
bolic pathway(s) (this can raise plasma drug levels) are well 
documented (Hancox et al., 2008; Vieweg & Wood, 2004) 
and coadministration of erythromycin with other drugs that 
inhibit or are metabolized by CYP3A4 or with QTc prolong-
ing drugs has been identified as a major risk factor (reviewed 
in Hancox et al., 2014). To our knowledge, this study is the 
first to characterize in vitro interactions of erythromycin with 
a range of internal and external hERG blockers. Our report 
is in line with recent recommendations from the European 
Medicines Agency (EMA) advising pharmacodynamics dis-
ruption (PD) interaction studies when two drugs, likely to be 
used concomitantly, compete for the same target (http://www.
ema.europa.eu/docs/enGB/docum entli brary /Annua lrepo 
rt/2016/05/WC500 206482.pdf). Our study provides further 
understanding of hERG blocking drug interactions, in partic-
ular involving erythromycin, and could potentially contribute 
to better preclinical assessment of the arrhythmogenic risk 
related to polypharmacy. It also suggests that caution should 
be exercised in considering administration of more than one 
hERG interacting drug to mitigate drug-induced LQTS, as 
the preponderance of data suggest that protection is unlikely 
to occur.
This study scrutinized the effects of erythromycin modu-
lation of hERG sensitivity to a series of pore (internal) and 
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external inhibitors at the channel level. It therefore excluded 
any interference from metabolic pathways mediated by the en-
zymes of the cytochrome P450 system known to metabolize 
erythromycin extensively. Erythromycin potency against iso-
enzymes of the cytochrome P450 is well documented to cause 
increased serum concentration of terfenadine, and thereby en-
hanced sensitivity to drug-induced QT interval prolongation 
(Biglin, Faraon, Constance, & Lieh-Lai, 1994; Paris, Parente, 
Bruschetta, Guzman, & Niarchos, 1994). The synergistic in-
teraction resulting from the combination of terfenadine with 
erythromycin as described here could constitute an additional 
factor to explain the increased susceptibility to QT prolonga-
tion consecutive to the coadministration of both inhibitors.
5 |  CONCLUSIONS
Our data indicate that in the setting of drug-induced delayed 
cardiac repolarization and associated arrhythmia, reversing 
hERG channel blockade by way of pharmacological antago-
nism with low concentrations of the macrolide antibiotic 
drug erythromycin would not constitute an attractive adjunct 
or replacement treatment. Erythromycin appeared to poten-
tially act through one intracellular-binding site and one extra-
cellular one that may participate in the modulation of hERG 
pharmacological block by some of hERG’s pore inhibitors. 
Utilizing alanine scanning mutagenesis, interactions of the 
S5-pore linker with the intracellular regions of the channel 
involved in hERG block could be probed in order to under-
stand allosteric interactions between external and internal 
(pore) drug sites in hERG.
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